This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Bos, J. M. Articles by Ackerman, M. J. PubMed Articles by Bos, J. M. Articles by Ackerman, M. J. Related Collections Related Article

FOCUS ISSUE: HYPERTROPHIC CARDIOMYOPATHY: STATE-OF-THE-ART PAPER

Diagnostic, Prognostic, and Therapeutic Implications of Genetic Testing for Hypertrophic Cardiomyopathy

J. Martijn Bos, MD^_*, Jeffrey A. Towbin, MD and Michael J. Ackerman, MD, PhD^_*,,_*

^_* Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota
Departments of Medicine, Pediatrics, and Molecular Pharmacology & Experimental Therapeutics, Divisions of Cardiovascular Diseases and Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota
The Heart Institute, Division of Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Manuscript received October 28, 2008; revised manuscript received February 20, 2009, accepted February 24, 2009.

^_* Reprint requests and correspondence: Dr. Michael J. Ackerman, Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory, Guggenheim 501, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905 (Email: ackerman.michael{at}mayo.edu).

Over the last 2 decades, the pathogenic basis for the most common heritable cardiovascular disease, hypertrophic cardiomyopathy (HCM), has been investigated extensively. Affecting approximately 1 in 500 individuals, HCM is the most common cause of sudden death in young athletes. In recent years, genomic medicine has been moving from the bench to the bedside throughout all medical disciplines including cardiology. Now, genomic medicine has entered clinical practice as it pertains to the evaluation and management of patients with HCM. The continuous research and discoveries of new HCM susceptibility genes, the growing amount of data from genotype-phenotype correlation studies, and the introduction of commercially available genetic tests for HCM make it essential that the modern-day cardiologist understand the diagnostic, prognostic, and therapeutic implications of HCM genetic testing.

Key Words: hypertrophic • cardiomyopathy • genomics

Abbreviations and Acronyms   ACE = angiotensinogen-I converting enzyme   DCM = dilated cardiomyopathy   HCM = hypertrophic cardiomyopathy   LV = left ventricle/ventricular   LVH = left ventricular hypertrophy   LVNC = left ventricular noncompaction   miRNA = micro-ribonucleic acid   RAAS = renin-angiotensin-aldosterone system   RNA = ribonucleic acid

Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A24. [Full Text] [PDF]